Center for Biophysics and Quantitative Biology

Paul J Hergenrother


Computational and structure-based design of enzyme inhibitors; explorations of small molecule-RNA binding

Research Interests

Research Description

The overarching goal of our research is to use small organic compounds to identify novel cellular targets that can be exploited in the treatment of diseases including cancer, neurodegeneration, and drug-resistant bacteria. The compounds used to validate these novel drug targets are identified through a variety of approaches, including natural product synthesis, combinatorial chemistry, structure-based design, and high-throughput screening. In the process, novel methods for the synthesis of various chemical building blocks and for biological assays often need to be developed. In addition, we work closely with the local medical community and perform tests directly on patient samples.


B.S., 1994, University of Notre Dame (Chemistry)
Ph.D., 1999, University of Texas at Austin (Chemistry)
Postdoc., 1999-2001, Department of Chemistry and Chemical Biology, Harvard University


American Cancer Society Postdoc Fellow
Beckman Young Investigator Award
Alfred P Sloan Foundation Fellowship Recipient
American Cancer Society Research Scholar